Novartis data at ECTRIMS to highlight innovative approach to reimagining care for people living with multiple sclerosis (MS)

• Novartis will present 34 abstracts from leading MS portfolio, including the highly anticipated results from the Phase III trial of investigational B-cell therapy ofatumumab (OMB157), data for Mayzent^® (siponimod) and Gilenya^® (fingolimod)
  
• Results from head-to-head Phase III ASCLEPIOS studies evaluating efficacy and safety of ofatumumab, an investigational B-cell therapy that potentially can be administered subcutaneously at home by patients with relapsing multiple sclerosis, will be presented for the first time[1]
  
• Additional EXPAND data support that patients benefit from Mayzent treatment, which has a positive impact on cognition and prolonged mobility[2-4]
  
• New data on neurofilaments and glial fibrillary acidic protein support their use as potential clinical biomarkers of disease activity, treatment response and disability progression, helping to pave the way to introduce new monitoring instruments beyond MRI[5,6]

Novartis, a global leader in neuroscience, announced today it will present 34 abstracts at the upcoming 35^th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 11–13, 2019 in Stockholm, Sweden. The breadth of data being presented highlights the company’s commitment to improving the lives of people living with MS, no matter where they are in their disease journey.  

“We are excited to be presenting new data at ECTRIMS from across our unique portfolio and demonstrating how we are leading the way in reimagining MS care,” said Danny Bar-Zohar, Global Head, Neuroscience Development for Novartis Pharmaceuticals. “Novartis is dedicated to advancing the science and developing transformative medicines so that we can solve the significant unmet needs that still exist in the treatment of MS.”

Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

References

[1] Hauser S, et al. Efficacy and Safety of Ofatumumab Versus Teriflunomide in Relapsing Multiple Sclerosis: Results of the Phase 3 ASCLEPIOS I and II Trials. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 2019.
[2]  Vermersch P, et al. Siponimod Delays the Time to Wheelchair in Patients with SPMS: Results from the EXPAND study. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 2019.
[3]  Arnold D, et al. Relationship Between Grey Matter Atrophy, Disability and Cognition in Patients with Secondary Progressive Multiple Sclerosis: Analysis from the EXPAND Study. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 2019.
[4]  Arnold D, et al. Effect of Siponimod on Cortical Grey Matter and Thalamic Volume in Patients with Secondary Progressive Multiple Sclerosis - Results of the EXPAND Study. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 2019.
[5]  Kuhle J, et al. Elevated levels of plasma neurofilament light at months 6 and 12 after fingolimod treatment initiation predict disability worsening in patients with relapsing-remitting multiple sclerosis. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 2019.
[6] Kuhle J, et al. Plasma Glial Fibrillary Acidic Protein correlates with characteristics of advanced disease and treatment response in secondary progressive multiple sclerosis. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 2019.